Stanford University
Showing 1-10 of 285 Results
-
Marcel Fafchamps
Senior Fellow at the Freeman Spogli Institute for International Studies, Emeritus
Current Research and Scholarly InterestsSee my personal website for all my recent working papers.
-
Marc Fagel
Lecturer
BioMarc Fagel spent nearly 30 years as a Bay Area securities litigator with a focus on Securities and Exchange Commission (SEC) enforcement. After six years as an associate at Morrison & Foerster, Marc joined the SEC’s San Francisco Regional Office as an enforcement staff attorney, investigating matters including insider trading, public company financial fraud, and misconduct by investment professionals. Marc later became the office’s Head of Enforcement and, from 2008-2013, served as Regional Director, overseeing the SEC’s enforcement and inspection programs throughout Northern California and the Pacific Northwest and managing the office’s staff of over 100 professionals.
After nearly 16 years with the SEC, Marc joined Gibson Dunn as a partner in the firm’s San Francisco and Palo Alto Offices, where he served as Co-Chair of the firm’s national Securities Enforcement practice group. Marc’s practice focused on representing public companies and their officers and directors, as well as financial institutions and investment managers, in investigations by the SEC, the Department of Justice, and other state and federal regulatory authorities.
In 2019, Marc retired from the full-time practice of law, and has since dedicated himself to writing and volunteer activities. Marc is currently a member of the Board of Directors of the Giffords Law Center to Prevent Gun Violence and the Board of Advisors of VoteRiders, a non-partisan organization dedicated to helping voters secure ID required by increasingly draconian voter ID requirements. He volunteers with local food banks, and has served as an election monitor for recent state and national elections.
Marc received his undergraduate degree from Princeton University and graduated with honors from the University of Chicago Law School. -
Norah Fahim
Advanced Lecturer
Current Research and Scholarly InterestsSPECIALIZATION: Digital Rhetoric, Narrative Inquiry, Writing Program Administration, Teaching English to Speakers of Other Languages, and Second Language Writing
-
Robert Michael Fairchild
Assistant Professor of Medicine (Immunology and Rheumatology)
Current Research and Scholarly InterestsDr. Fairchild’s research focuses on musculoskeletal and organ-based ultrasound in rheumatic disease, including arthritis, calcinosis, vascular pathology, and interstitial lung disease. He develops ultrasound-based outcome measures and leads projects applying deep learning and explainable AI to imaging. He also performs ultrasound-guided synovial biopsies to support translational and clinical research.
-
Bita Fakhri, MD, MPH
Assistant Professor of Medicine (Hematology)
BioDr. Bita Fakhri is Assistant Professor of Medicine in the Division of Hematology at Stanford University School of Medicine. She specializes in the treatment of chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), hairy cell leukemia, and other hematologic malignancies. As a clinical scientist, Dr. Fakhri is dedicated to caring for patients, teaching trainees, and researching novel therapies for patients with CLL/SLL. Dr. Fakhri has co-authored numerous publications on topics including CLL, novel targeted agents, and cellular therapies for patients with hematologic malignancies. Currently, Dr. Fakhri is the director of the CLL clinical trial portfolio at Stanford. Additionally, in her role as the DEI ambassador of the Division of Hematology, her main focus is to enhance trial equity among underserved and marginalized populations in the Stanford catchment area.
-
Titilola Falasinnu
Assistant Professor of Medicine (Immunology and Rheumatology) and, by courtesy, of Anesthesiology, Perioperative and Pain Medicine (Adult Pain)
BioI am primarily a lupus researcher and identify as a pain scientist and methodologist in this field. Systemic lupus erythematosus (SLE) disproportionately affects women and racial minorities and is the fifth most common cause of death among 15- to 24-year-old Black and Hispanic women in the U.S., highlighting its significant public health impact. More than half of patients with SLE experience chronic pain, often secondary to SLE itself or overlapping conditions (e.g., migraines, low back pain, fibromyalgia), contributing significantly to disability and impaired quality of life. Chronic pain is not merely a symptom but a disease in its own right—one that deserves the same rigorous study and clinical attention as comorbidities like kidney disease and cardiovascular disease in rheumatology. The enormous global burden of chronic pain underscores the urgent need for a clear, standardized definition of pain as a disease, particularly in autoimmune rheumatic diseases where pain can arise from inflammatory, nociplastic, and biopsychosocial mechanisms. Without recognizing pain as a distinct disease entity, its mechanisms remain poorly understood, and effective treatment strategies remain underdeveloped.
I am a co-Principal Investigator of the Pain Intelligence Lab, where our mission is to advance the study of pain as a disease in rheumatology through two primary objectives. First, we develop and validate computational methods that enable clinicians and researchers to leverage electronic health records, administrative claims, and disease registries to study chronic pain as a distinct disease entity in rheumatology. By applying machine learning, natural language processing, and real-world data analysis, we seek to enhance pain phenotyping, classify distinct pain subtypes, and develop predictive models for treatment response. Second, we use a biopsychosocial framework to examine the predictive power of biomarkers and psychosocial measures in rheumatologic pain. By integrating biological, psychological, and social determinants of pain, we aim to conduct rigorous, patient-oriented research that translates targeted assessments into mechanistically informed, personalized treatment approaches for optimized clinical care. Ultimately, my long term career goal is to bridge the gap between research and clinical practice, ensuring that pain management in autoimmune rheumatic diseases is precise, equitable, and optimized for improved patient outcomes.
